Impact of genetic and acquired alteration in cytochrome P450 system on pharmacologic and clinical response to clopidogrel

Pharmacology and Therapeutics

Volumn 125, Issue 2, 2010, Pages 249-259

  Ma, Terry K W ^a   Lam, Yat Yin ^a   Tan, Victoria P ^b   Kiernan, Thomas J ^c   Yan, Bryan P ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Clopidogrel; Cytochrome P450; Polymorphism; Proton pump inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ATORVASTATIN; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; ESOMEPRAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OMEPRAZOLE; PACLITAXEL; PANTOPRAZOLE; PLACEBO; PRASUGREL; PRAVASTATIN; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; RAPAMYCIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTIPLATELET ACTIVITY; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CORONARY STENT; DNA POLYMORPHISM; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE LOSS; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; PRIORITY JOURNAL; REPEAT REVASCULARIZATION; REVASCULARIZATION; REVIEW; SIDE EFFECT; STENT THROMBOSIS; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS;

EID: 77249155077     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2009.10.008     Document Type: Review

References (102)

1. Adams P.C., Badimon J.J., Badimon L., Chesebro J.H., Fuster V. Role of platelets in atherogenesis: Relevance to coronary arterial restenosis after angioplasty. Cardiovasc Clin 1987, 18(1):49-71.
2. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Alfonso F., Macaya C., Bass T.A., et al. Variability in individual responsiveness to clopidogrel: Clinical implications, management, and future perspectives. J Am Coll Cardiol 2007, 49(14):1505-1516.
3. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramírez C., Cavallari U., Trabetti E., et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Haemost 2005, 116(60):491-497.
4. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramírez C., Cavallari U., Trabetti E., et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol 2006, 26(8):1895-1900.
5. Angiolillo D.J., Fernández-Ortiz A., Bernardo E., Ramírez C., Sabaté M., Bañuelos C., et al. High clopidogrel loading dose during coronary stenting: Effects on drug response and interindividual variability. Eur Heart J 2004, 25(21):1903-1910.
6. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: Results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007, 115(6):708-716.
7. Antman E.M., Wiviott S.D., Murphy S.A., Voitk J., Hasin Y., Widimsky P., et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention a TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction) analysis. J Am Coll Cardiol 2008, 51(21):2028-2033.
8. Aubert R.E., Epstein R.S., Teagarden J.R., Xia F., Yao J., Desta Z., et al. Proton pump inhibitors effect on clopidogrel effectiveness: The Clopidogrel Medco Outcomes Study (Abstract). Circulation 2008, 118:S_815.
9. Bhatt D.L., Scheiman J., Abraham N.S., Antman E.M., Chan F.K., Furberg C.D., et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation 2008, 118(18):1894-1909.
10. Blagojevic A., Delaney J.A., Lévesque L.E., Dendukuri N., Boivin J.F., Brophy J.M. Investigation of an interaction between statins and clopidogrel after percutaneous coronary intervention: a cohort study. Pharmacoepidemiol Drug Saf 2009, 18(5):362-369.
11. Brandt J.T., Close S.L., Iturria S.J., Payne C.D., Farid N.A., Ernest C.S., et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007, 5(12):2429-2436.
12. Brophy J.M., Babapulle M.N., Costa V., Rinfret S. A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention. Am Heart J 2006, 152(2):263-269.
13. Buonamici P., Marcucci R., Migliorini A., Gensini G.F., Santini A., Paniccia R., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stentthrombosis. J Am Coll Cardiol 2007, 49(24):2312-2317.
14. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., Belder R., et al. PROVE-IT-TIMI 22 Investigators Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350(15):1495-1504.
15. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348(9038):1329-1339.
16. Clarke T.A., Waskell L.A. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003, 31(1):53-59.
17. Collet J.P., Hulot J.S., Pena A., Villard E., Esteve J.B., Silvain J., et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 2009, 373((9660):309-317.
18. Dunn S.P., Macaulay T.E., Brennan D.M., Campbell C.L., Charnigo R.J., Smyth S.S., et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008, 118:815A. (abstract).
19. Ernesto O., Martin H., Ronald D. Clopidogrel resistance. Heart Lung Circ 2007, 16(3):S17-S28.
20. Evans W.E., McLeod H.L. Pharmacogenomics: Drug disposition, drug targets, and side effects. N Engl J Med 2003, 348(6):538-549.
21. Farid N.A., Payne C.D., Small D.S., Winters K.J., Ernest C.S., Brandt J.T., et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007, 81(5):735-741.
22. Frere C., Cuisset T., Morange P.E., Quilici J., Camoin-Jau L., Saut N., et al. Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008, 101(8):1088-1093.
23. Fontana P., Hulot J.S., De Moerloose P., Gaussem P. Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects. J Thromb Haemost 2007, 5(10):2153-2155.
24. Gilard M., Arnaud B., Cornily J.C., Le Gal G., Lacut K., Le Calvez G., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008, 51(3):256-260.
25. Gilard M., Arnaud B., Le Gal G., Abgrall J.F., Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006, 4(11):2508-2509.
26. Giusti B., Gori A.M., Marcucci R., Saracini C., Sestini I., Paniccia R., et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007, 17(12):1057-1064.
27. Giusti B., Gori A.M., Marcucci R., Saracini C., Sestini I., Paniccia R., et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am J Cardiol 2009, 103(6):806-811.
28. Gurbel P.A., Bliden K.P., Hayes K.M., Yoho J.A., Herzog W.R., Tantry U.S. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005, 45(9):1392-1396.
29. Gurbel P.A., Bliden K.P., Hiatt B.L., O'Connor C.M. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107(23):2908-2913.
30. Gurbel P.A., Bliden K.P., Samara W., Yoho J.A., Hayes K., Fissha M.Z., et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: Results from the CREST Study. J Am Coll Cardiol 2005, 46(10):1827-1832.
31. Gurbel P.A., Cummings C.C., Bell C.R., Alford A.B., Meister A.F., Serebruany V.L., et al. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2003, 145(2):239-247.
32. Han Y.L., Wang B., Li Y., Xu K., Wang S.L., Jing Q.M., et al. A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation. Chin Med J 2009, 122(7):793-797.
33. Herbert J.M., Savi P. P2Y12, a new platelet ADP receptor, target of clopidogrel. Semin Vasc Med 2003, 3(2):113-122.
34. Ho P.M., Maddox T.M., Wang L., Fihn S.D., Jesse R.L., Peterson E.D., et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009, 301(9):937-944.
35. Hochholzer W., Trenk D., Bestehorn P., Fischer B., Valina C.M., Ferenc M., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006, 48(9):1742-1750.
36. Hochholzer W., Trenk D., Frundi D., Blanke P., Fischer B., Andris K., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005, 111(20):2560-2564.
37. Horn J. Review article: Relationship between the metabolism and efficacy of proton pump inhibitors - Focus on rabeprazole. Aliment Pharmacol Ther 2004, 20(Suppl 6):11-19.
38. Hulot J.S., Bura A., Villard E., Azizi M., Remones V., Goyenvalle C., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006, 108(7):2244-2247.
39. Ishizaki T., Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - Emphasis on rabeprazole. Aliment Pharmacol Ther 1999, 13(3):27-36.
40. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005, 293(17):2126-2130.
41. Jeremias A., Sylvia B., Bridges J., Kirtane A.J., Bigelow B., Pinto D.S., et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004, 109(16):1930-1932.
42. Juurlink D.N., Gomes T., Ko D.T., Szmitko P.E., Austin P.C., Tu J.V., et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009, 180(7):713-718.
43. Kim K.A., Park P.W., Hong S.J., Park J.Y. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008, 84(2):236-242.
44. Kim K.A., Park P.W., Park J.Y. Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur J Clin Pharmacol 2008, 64(6):589-597.
45. King S.B., Smith S.C., Hirshfeld J.W., Jacobs A.K., Morrison D.A., Williams D.O., et al. Focused update of the ACC/ AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Circulation 2007, 117(2):261-295. [Erratum, Circulation 2008;117(6):e161].
46. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001, 27(6):383-391.
47. Lau W.C., Gurbel P.A., Watkins P.B., Neer C.J., Hopp A.S., Carville D.G., et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004, 109(2):166-171.
48. Lau W.C., Waskell L.A., Watkins P.B., Neer C.J., Horowitz K., Hopp A.S. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 2003, 107(1):32-37.
49. Le Breton H., Plow E.F., Topol E.J. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 1996, 28(7):1643-1651.
50. Lim M.J., Spencer F.A., Gore J.M., Dabbous O.H., Agnelli G., Kline-Rogers E.M., et al. Impact of combined pharmacologic treatment with clopidogrel and a statin on outcomes of patients with non-ST-segment elevation acute coronary syndromes: Perspectives from a large multinational registry. Eur Heart J 2005, 26(11):1063-1069.
51. Marteau F., Le Poul E., Communi D., Communi D., Labouret C., Savi P., et al. Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol 2003, 64(1):104-112.
52. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic vents in patients with acute myocardial infarction. Circulation 2004, 109(25):3171-3175.
53. Mega J.L., Close S.L., Wiviott S.D., Shen L., Hockett R.D., Brandt J.T., et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360(4):354-362.
54. Michelson A.D. Methods for the measurement of platelet function. Am J Cardiol 2009, 103(3 Suppl):20A-26A.
55. Michelson A.D., Frelinger A.L., Furman M.I. Current options in platelet function testing. Am J Cardiol 2006, 98(10A):4N-10N.
56. Mitsios J.V., Papathanasiou A.I., Rodis F.I., Elisaf M., Goudevenos J.A., Tselepis A.D. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5weeks in patients with acute coronary syndromes. Circulation 2004, 109(11):1335-1338.
57. Müller I., Besta F., Schulz C., Li Z., Massberg S., Gawaz M. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 2003, 108(18):2195-2197.
58. Müller I., Seyfarth M., Rüdiger S., Wolf B., Pogatsa-Murray G., Schömig A., et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001, 85(1):92-93.
59. Mukherjee D., Kline-Rogers E., Fang J., Munir K., Eagle K.A. Lack of clopidogrel-CYP3A4 statin interaction in patients with acute coronary syndrome. Heart 2005, 91(1):23-26.
60. Nebert D.W., Russell D.W. Clinical importance of the cytochromes P450. Lancet 2002, 360(9340):1155-1162.
61. Neubauer H., Günesdogan B., Hanefeld C., Spiecker M., Mügge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function: a flow cytometry study. Eur Heart J 2003, 24(19):1744-1749.
62. Nguyen T.A., Diodati J.G., Pharand C. Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol 2005, 45(8):1157-1164.
63. O'Donoghue M., Wiviott S.D. Clopidogrel response variability and future therapies: Clopidogrel: Does one size fit all? Circulation 2006, 114(22):e600-e606.
64. O'Donoghue M.L., Braunwald E., Antman E.M., Murphy S.A., Bates E.R., Rozenman Y., et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials. Lancet 2009, 374(9694):989-997.
65. Pereillo J.M., Maftouh M., Andrieu A., Uzabiaga M.F., Fedeli O., Savi P., et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 2001, 30(11):1288-1295.
66. Pinto Slottow T.L., Bonello L., Gavini R., Beauzile P., Sushinsky S.J., Scheinowitz M., et al. Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. Am J Cardiol 2009, 104(4):525-530.
67. Savi P., Beauverger P., Labouret C., Delfaud M., Salel V., Kaghad M., et al. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett 1998, 422(3):291-295.
68. Savi P., Combalbert J., Gaich C., Rouchon M.C., Maffrand J.P., Berger Y., et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994, 72(2):313-317.
69. Savi P., Herbert J.M., Pflieger A.M., Dol F., Delebassee D., Combalbert J., et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992, 44(3):527-532.
70. Savi P., Labouret C., Delesque N., Guette F., Lupker J., Herbert J.M. P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001, 283(2):379-383.
71. Savi P., Nurden P., Nurden A.T., Levy-Toledano S., Herbert J.M. Clopidogrel: A review of its mechanism of action. Platelets 1998, 9(3-4):251-255.
72. Savi P., Zachayus J.L., Delesque-Touchard N., Labouret C., Caroline H., Uzabiaga M.F., et al. The active metabolite of clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc Natl Acad Sci U S A 2006, 103(29):11069-11074.
73. Saw J., Brennan D.M., Steinhubl S.R., Bhatt D.L., Mak K.H., Fox K., et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J Am Coll Cardiol 2007, 50(4):291-295.
74. Saw J., Steinhubl S.R., Berger P.B., Kereiakes D.J., Serebruany V.L., Brennan D., et al. Lack of adverse clopidogrel atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003, 108(8):921-924.
75. Sibbing D., Stegherr J., Latz W., Koch W., Mehilli J., Dörrler K., et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 2009, 30(8):916-922.
76. Silber S., Albertsson P., Avilés F.F., Camici P.G., Colombo A., Hamm C., et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005, 26(8):804-847.
77. Siller-Matula J.M., Lang I., Christ G., Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008, 52(19):1557-1563.
78. Siller-Matula J.M., Spiel A.O., Lang I.M., Kreiner G., Christ G., Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009, 157(1):148.e1-5.
79. Simon T., Verstuyft C., Mary-Krause M., Quteineh L., Drouet E., Méneveau N., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009, 360(4):363-375.
80. Smith S.C., Allen J., Blair S.N., Bonow R.O., Brass L.M., Fonarow G.C., et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: Endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006, 113(19):2363-2372.
81. Smith S.M., Judge H.M., Peters G., Armstrong M., Fontana P., Gaussem P., et al. Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy. Platelets 2006, 17(4):250-258.
82. Spertus J.A., Kettelkamp R., Vance C., Decker C., Jones P.G., Rumsfeld J.S., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: Results from the PREMIER registry. Circulation 2006, 113(24):2803-2809.
83. Steinhubl S., Moliterno D.J. The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drugs 2005, 5(6):399-408.
84. Suh J.W., Koo B.K., Zhang S.Y., Park K.W., Cho J.Y., Jang I.J., et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006, 174(12):1715-1722.
85. Tan V.P., Yan B.P., Kiernan T.J., Ajani A.E. Risk and management of upper gastrointestinal bleeding associated with prolonged dual-antiplatelet therapy after percutaneous coronary intervention. Cardiovasc Revasc Med 2009, (1):36-44.
86. Thebault J.J., Kieffer G., Cariou R. Single-dose pharmacodynamics of clopidogrel. Semin Thromb Hemost 1999, 25(2):3-8.
87. Thebault J.J., Kieffer G., Lowe G.D., Nimmo W.S., Cariou R. Repeated dose pharmacodynamics of clopidogrel in healthy subjects. Semin Thromb Hemost 1999, 25(2):9-14.
88. Trenk D., Hochholzer W., Fromm M.F., Chialda L.E., Pahl A., Valina C.M., et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008, 51(20):1925-1934.
89. Trenk D., Hochholzer W., Frundi D., Stratz C., Valina C.M., Bestehorn H.P., et al. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost 2008, 99(1):174-181.
90. Umemura K., Furuta T., Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics to an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost 2008, 6(8):1439-1441.
91. Vinholt P., Poulsen T.S., Korsholm L., Kristensen S.R., Hallas J., Damkier P., et al. The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease. Thromb Haemost 2005, 94(2):438-443.
92. Von Beckerath N., Taubert D., Pogatsa-Murray G., Schömig E., Kastrati A., Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005, 112(19):2946-2950.
93. Von Beckerath N., Von Beckerath O., Koch W., Eichinger M., Schömig A., Kastrati A. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphateinduced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 2005, 16(3):199-204.
94. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361(11):1045-1057.
95. Wang T.H., Bhatt D.L., Topol E.J. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006, 27(6):647-654.
96. Wienbergen H., Gitt A.K., Schiele R., Juenger C., Heer T., Meisenzahl C., et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin. Am J Cardiol 2003, 92(3):285-288.
97. Wilkinson G.R. Drug metabolism and variability among patients in drug response. N Engl J Med 2005, 352(21):2211-2221.
98. Wiviott S.D., Braunwald E., McCabe C.H., Horvath I., Keltai M., Herrman J.P., et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITONTIMI 38 trial: A subanalysis of a randomised trial. Lancet 2008, 371(9621):1353-1363.
99. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357(20):2001-2015.
100. Wiviott S.D., Trenk D., Frelinger A.L., O'Donoghue M., Neumann F.J., Michelson A.D., et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007, 116(25):2923-2932.
101. Woulfe D., Yang J., Brass L. ADP and platelets: The end of the beginning. J Clin Invest 2001, 107(12):1503-1505.
102. Wrighton S.A., Schuetz E.G., Thummel K.E., Shen D.D., Korzekwa K.R., Watkins P.B. The human CYP3A subfamily: Practical considerations. Drug Metab Rev 2001, 32(3-4):339-361.